Monday, June 17, 2013

• Teva Strengthens Respiratory Franchise with Acquisition of MicroDose TherapeutxBusiness Wire( (Mon, Jun 17)

Friday, June 14, 2013

• Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 2013 International Congress of Parkinson’s Disease and Movement DisordersBusiness Wire( (Fri, Jun 14)

Wednesday, June 12, 2013

• Teva to Present at the Goldman Sachs 34th Annual Global Healthcare ConferenceBusiness Wire( (Wed, Jun 12)
• Teva Reaches Settlement Agreement with Pfizer and Nycomed Regarding Generic Protonix® (Pantoprazole) TabletsBusiness Wire( (Wed, Jun 12)
• TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPUS NEPHRITISThomson Reuters ONE( (Wed, Jun 12)
• Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus NephritisBusiness Wire( (Wed, Jun 12)

Monday, June 3, 2013

• Teva’s Lonquex®(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)Business Wire( (Mon, Jun 3)

Thursday, May 30, 2013

• Teva Announces FDA Acceptance of sNDA for a Higher Concentration Dose of COPAXONE® Given Three Times a WeekBusiness Wire( (Thu, May 30)

Tuesday, May 14, 2013

• Teva to Present at the Bank of America Merrill Lynch 2013 Health Care ConferenceBusiness Wire( (Tue, May 14)

Wednesday, May 8, 2013

• New Data Presented Demonstrates Ovulatory Effect of Teva Women’s Health’s Investigational 28-Day Oral ContraceptiveBusiness Wire( (Wed, May 8)
• Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S.PR Newswire( (Wed, May 8)
• Teva and Alexza Announce Teva’s License to Market ADASUVE® in the U.S.Business Wire( (Wed, May 8)
• Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S.PR Newswire( (Wed, May 8)